Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Prusogliptin with Warfarin, Digoxin, or Probenecid
NCT05045313Phase 1Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Oct 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of prusogliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Peak Plasma Concentration and Area Under the Curve. Started Oct 2021; status: completed.
02
Drugs
prusogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05045313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05045313.